Läsionale Therapieoptionen beim maligen Melanom

F. Kiecker; G. Poch; K. Farmer

doi:10.1007/s00761-018-0371-6

Loading next page...

Publisher: Springer Journals
Copyright: Copyright © 2018 by Springer Medizin Verlag GmbH, ein Teil von Springer Nature
Subject: Medicine & Public Health; Oncology
ISSN: 0947-8965
eISSN: 1433-0415
DOI: 10.1007/s00761-018-0371-6
Publisher site: See Article on Publisher Site

Abstract

Leitthema Onkologe 2018 · 24:464–471 F. Kiecker ·G. Poch ·K.Farmer https://doi.org/10.1007/s00761-018-0371-6 Klinik für Dermatologie, Venerologie und Allergologie, Charité Universitätsmedizin Berlin, Berlin, Online publiziert: 11. April 2018 Deutschland © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018 Läsionale Therapieoptionen beim maligen Melanom Bei Intransitmetastasen handelt se Patienten von vielen Studien ausge- morbiditäten eine Operation als unge- es sich um kutane oder subkutane, schlossen waren. Viele regionale Thera- eignet erscheinen lassen. Es sind jedoch lymphatische Absiedelungen von pieverfahrenwiez.B.Extremitätenperfu- keine Vergleichsdaten verfügbar, die die Melanomzellen zwischen dem sion und Elektrochemotherapie sind nie Ergebnisse nach Operation mit denen Primärtumor und der regionalen direkt miteinander verglichen worden; nach nicht operativen Therapiemaßnah- Lymphknotenstation. Es ist noch auch ihr Einﬂuss auf die Gesamtüberle- men gegenüberstellen. nicht klar, warum bei manchen benszeit ist nicht gut untersucht. Beim Aurft eten von zahlreichen In- Melanompatienten ausschließlich transitﬁliae kommen heutzutage viel frü- lokoregionäre Metastasen in her Systemtherapien zum Einsatz, de- In den meisten Melanom- den Lymphknoten, bei anderen ren Eﬀektivität den früher standardmä- leitlinien wird kein stan- nur auf der Intransitstrecke und ßig eingesetzten Chemotherapien deut- dardisiertes Vorgehen bei bei wiederum anderen beide lich überlegen ist. Dies führt auch dazu, Manifestationsformen auftreten. Intransitmetastasen angegeben dass Amputationen ganzer Gliedmaßen

Journal

Der Onkologe – Springer Journals

Published: Apr 11, 2018

References

Final version of 2009 AJCC melanoma staging and classification

Balch, CM; Gershenwald, JE; Soong, SJ
Prognosis and determinants of outcome following loco-regional or distant recurrence in patients with cutaneous melanoma

Francken, AB; Accortt, NA; Shaw, HM
Surgical management of melanoma: an EORTC Melanoma Group Survey

Testori, A; Soteldo, J; Powell, B
Surgical treatment of melanoma: a survey of Italian hospitals

Testori, A; Chiarion Sileni, V; Stanganelli, I
Alternative for the treatment of local advanced disease: electrochemotherapy, limb pefusion, limb infusion, intralesional Il2. What is the role?

Testori, A; Intelisano, A; Verrecchia, F
Local and intralesional therapy of in-transit melanoma metastases

Testori, A; Faries, MB; Thompson, JF
Major amputation for advanced melanoma: an epidemiological study

Ebskov, LB
Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit

Creech, O; Krementz, ET; Ryan, RF; Winblad, JN
Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics

Benckhuijsen, C; Kroon, BB; Geel, AN; Wieberdink, J
Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions

Wieberdink, J; Benckhuysen, C; Braat, RP
Optimization of isolated hyperthermic limb perfusion

Omlor, G
Selective heat sensitivity of cancer cells. Biochemical and clinical studies

Cavaliere, R; Ciocatto, EC; Giovanella, BC
Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma

Clark, J; Grabs, AJ; Parsons, PG
The application of hyperthermia in regional chemotherapy

Filippo, F; Anza, M; Rossi, CR
Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters

Alexander, HR; Fraker, DL; Bartlett, DL
Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions

Vrouenraets, BC; Klaase, JM; Kroon, BB
Thirty-five years of isolated limb perfusion for melanoma: indications and results

Vrouenraets, BC; Nieweg, OE; Kroon, BB
Prognostic factors influencing tumor response, loco-regional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion

Filippo, F; Giacomini, P; Rossi, CR
Current uses of isolated limb perfusion in the clinic and a model system for new strategies

Eggermont, AMM; Wilt, JHW; Hagen, TLM
Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group

Hafstrom, L; Rudenstam, CM; Blomquist, E
Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response

Aloia, TA; Grubbs, E; Onaitis, M
Isolated limb perfusion for unresectable melanoma of the extremities

Noorda, EM; Vrouenraets, BC; Nieweg, OE
TNF dose reduction in isolated limb perfusion

Grunhagen, DJ; Wilt, JH; Geel, AN
Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advancedmelanoma and soft-tissue sarcoma

Hayes, AJ; Neuhaus, SJ; Clark Thomas, MAJM
Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs

Thompson, JF; Gianoutsos, MP
One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases

Grunhagen, DJ; Brunstein, F; Graveland, WJ; Geel, AN; deWilt, JH; Eggermont, AM
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

Wilt, JH; Hagen, TL; Boeck, G
Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs

Lejeune, FJ; Eggermont, AM
Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases

Rossi, CR; Pasquali, S; Mocellin, S
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020

Cornett, WR; McCall, LM; Petersen, RP
Systemic leakage during isolated limb perfusion for melanoma

Klaase, JM; Kroon, BB; Geel, AN
Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?

Hoekstra, HJ; Veerman, K; Ginkel, RJ
Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion

Thompson, JF; Waugh, RC; Saw, RPM; Kam, PCA
Tourniquet infusion versus hyperthermic perfusion

Karakousis, CP; Kanter, PM; Park, HC; Sharma, SD; Moore, R; Ewing, JH
Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy

Roberts, MS; Wu, ZY; Siebert, GA; Anissimov, YG; Thompson, JF; Smithers, BM
Outcomes of isolated limb infusion for melanoma. A 14-year experience

Kroon, HM; Moncrieff, M; Kam, PC; Thompson, JF
Isolated limb infusion for melanoma and sarcoma. A good alternative for isolated limb perfusion with cytotoxic drugs

Kroon, HM; Thompson, JF; Hoekstra, HJ
Australian multicenter study of isolated limb infusion for melanoma

Kroon, HM; Coventry, BJ; Giles, MH
Outcomes of the use of isolated limb infusion for soft tissue sarcoma of the extremity

Moncrieff, MD; Kroon, HM; Kam, PC; Stalley, PD; Scolyer, RA; Thompson, JF
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US

Beasley, GM; Caudle, A; Petersen, RP
Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion

Mian, R; Henderson, MA; Speakman, D; Finkelde, D; Ainslie, J; McKenzie, A
Preoperative isolated limb infusion of doxorubicin and external irradiation for limb-threatening soft tissue sarcomas

Hegazy, MA; Kotb, SZ; Sakr, H
FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma

Ryan, ER; Hill, AD; Skehan, SJ
Isolated limb infusion for intransit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion

Beasley, GM; Petersen, RP; Yoo, J
Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma

Lindner, P; Doubrovsky, A; Kam, PCA; Thompson, JF
Isolated limb infusion for malignant melanoma: predictors of response and outcome

Barbour, AP; Thomas, J; Suffolk, J
Does increased experience with isolated limb infusion for advanced melanoma influence outcome? A comparison of two treatment periods at a single institution

Huismans, AM; Kroon, HM; Kam, PCA; Thompson, JF
A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity

Brady, MS; Brown, K; Patel, A; Fisher, C; Marx, W
Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin-D in melanoma patients

Kroon, HM; Moncrieff, M; Kam, PC; Thompson, JF
Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced loco-regional melanoma

Kroon, HM; Lin, DY; Kam, PC; Thompson, JF
Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma

Kroon, HM; Lin, DY; Kam, PC; Thompson, JF
A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma

Beasley, GM; McMahon, N; Sanders, G
Future directions in regional treatment strategies for melanoma and sarcoma

Beasley, GM; Ross, MI; Tyler, DS
Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma

Dossett Lesly, A; Ben-Shabat, I; Olofsson Bagge, R; Zager, JS
Novel dermatologic uses of the immune response modifier imiquimod 5 % cream

Berman, B; Poochareon, VN; Villa, AM
Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis

Turza, K; Dengel, LT; Harris, RC
Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma

Damian, DL; Saw, RP; Thompson, JF
Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene

Cohen, MH; Jessup, JM; Felix, EL
Intralesional therapy for advanced melanoma: promise and limitation

Agarwala Sanjiv, S
Immunological factors which influence response to immunotherapy in malignant melanoma

Morton, D; Eilber, F; Malmgren, R; Wood, W
Intralesional immunotherapy of melanoma with BCG

Rosenberg, S; Rapp, H
Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases

Mastrangelo, M; Bellet, R; Berkelhammer, J; Clark, WJ
Complications of BCG immunotherapy in patients with cancer

Sparks, F; Silverstein, M; Hunt, J; Haskell, C; Pilch, Y; Morton, D
Intralesional interferon-alpha therapy in advanced malignant melanoma

Wussow, P; Block, B; Hartmann, F; Deicher, H
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

Radny, P; Caroli, UM; Bauer, J
Phase II trial of a Toll-like receptor 9‑activating oligonucleotide in patients with metastatic melanoma

Pashenkov, M; Goess, G; Wagner, C
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma

Kaufman, HL; Kim, DW; DeRaffele, G; Mitcham, J; Coffin, RS; Kim-Schulze, S
Talimogene laherparepvec improves durable responce rate in patients with advanced melanoma

Andtbacka, R; Kaufman, H; Collichio, F
Talimogene laherparepvec in combination with Ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma

Puzanov, I; Milhem, MM; Minor, D
Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer

Toomey, P; Kodumudi, K; Weber, A
Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions

Sarnaik, A; Crago, G; Liu, H
Generation of an antitumor response and immunity using a small molecule drug (PV-10)

Dees, HC; Blair, S; Harkins, J
Distribution and fate of rose bengal

Bocci, V
On the distribution and kinetics of injected I131 rose bengal. An experimental study with special reference to the evaluation of liver function

Meurman, L
Phase 2 study of intralesional PV-10 in refractory metastatic melanoma

Thompson, JF; Agarwala, SS; Smithers, BM
A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy

Foote, MC; Burmeister, BH; Thomas, J; Smithers, BM
A phase 2 study of intralesional PV-10 followed by radiotherapy for localized in transit or recurrent metastatic melanoma

Foote, MC; Burmeister, BH; Thomas, J
Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1

Liu, H; Innamarato, PP; Kodumudi, K
T cell mediated immunity after combination therapy with intralesional PV-10 and coinhibitory blockade in a melanoma model

Weber, AM; Liu, H; Kodumudi, KN
In vivo evolution of tumour cells after the generation of doublestrand DNA breaks

Mekid, H; Tounekti, O; Spatz, A; Cemazar, M; Kebir, FZ; Mir, LM
Bases and rationale of the electrochemotherapy

Mir, L
Electrochemotherapy: an emerging cancer treatment

Sadadcharam, M; Soden, DM; O’Sullivan, GC
Electrochemotherapy: aspects of preclinical development and early clinical experience

Larkin, JO; Collins, CG; Aarons, S
Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients

Rudolf, Z; Stabuc, B; Cemazr, M
Bleomycin-mediated electrochemotherapy of metastatic melanoma

Glass, LF; Pepine, ML; Fenske, NA; Jaroszeski, M; Reintgen, DS; Heller, R
Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin

Heller, R; Jaroszeski, MJ; Reintgen, DS
Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy

Mir, LM; Glass, LF; Sersa, G
Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients

Campana, LG; Mocellin, S; Basso, M
Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases

Quaglino, P; Mortera, C; Osella-Abate, S
Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach

Testori, A; Tosti, G; Martinoli, C
Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes

Mir, L; Gehl, J; Sersa, G
Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors

Byrne, CM; Thompson, JF
Treatment of metastatic melanoma with electrochemotherapy

Campana, LG; Testori, A; Mozzillo, N; Rossi, CR
Electrochemotherapy for treatment of locally advanced superficial cancer: results from a single institution

Pennacchioli, E; Intelisano, A; Verrecchia, F
Utility of electrochemotherapy in melanoma treatment

Testori, A; Rossi, CR; Tosti, G
Electrochemotherapy an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study

Marty, M; Gregor, S; Garbay, JR
Treatment efficacy with electrochemotherapy: a multi-institutional prospective observational study on 376 patients with superficial tumors

Campana, LG; Testori, A; Curatolo, P
Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients

Campana, LG; Mocellin, S; Basso, M
Electrochemotherapy for disseminated superficial metastasesfrom malignant melanoma

Campana, LG; Valpione, S; Mocellin, S
Tumour destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumour responses

Roux, S; Bernat, C; Al-Sakere, B
Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vessels

Markelc, B; Sersa, G; Cemazar, M
Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy

Gerlini, G; Sestini, S; Gennaro, P; Urso, C; Pimpinelli, N; Borgognoni, L
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy

Mozzillo, N; Simeone, E; Benedetto, L
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis

Heppt, MV; Eigentler, TK; Kähler, KC; Herbst, RA; Göppner, D; Gambichler, T; Ulrich, J; Dippel, E; Loquai, C; Schell, B; Schilling, B; Schäd, SG; Schultz, ES; Matheis, F; Tietze, JK; Berking, C
Combination of radiotherapy and immune checkpoint inhibitors

Pilones, KA; Vanpouille-Box, C; Demaria, S

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Läsionale Therapieoptionen beim maligen Melanom

Läsionale Therapieoptionen beim maligen Melanom

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Läsionale Therapieoptionen beim maligen Melanom

Läsionale Therapieoptionen beim maligen Melanom

Abstract

Journal

Recommended Articles

References

Our policy towards the use of cookies